Effective treatment of coprophagia in a patient with schizophrenia with the novel atypical antipsychotic drug perospirone.

Abstract

Here we report on a patient with schizophrenia who suffered from medication-refractory coprophagia. Although there were few cases in which psychotropic medication was effective against coprophagia, we encountered a patient with schizophrenia in whom coprophagia rapidly disappeared after treatment with perospirone, a novel atypical antipsychotic drug of the serotonin-dopamine antagonist (SDA) type. Perospirone has a uniquely high affinity for serotonin-1A receptors, and it could be speculated that perospirone, as a serotonin-1A receptor agonist combined with SDA, may have greater efficacy for treatment-refractory symptoms of schizophrenia. Thus, perospirone is an agent with possible efficacy for medication-refractory schizophrenia.

• Authors: K I Harada, K Yamamoto, T Saito
• Journal: Pharmacopsychiatry (Pharmacopsychiatry) Vol. 39 Issue 3 Pg. 113 (May 2006) ISSN: 0176-3679 [Print] Germany
• PMID: 16721701 (Publication Type: Case Reports, Letter)

Chemical References

• Antipsychotic Agents
• Indoles
• Isoindoles
• Thiazoles
• Receptor, Serotonin, 5-HT1A
• perospirone

Topics

• Antipsychotic Agents (adverse effects, therapeutic use)
• Brain (drug effects)
• Follow-Up Studies
• Human Coprophagia (drug therapy, psychology)
• Humans
• Indoles (adverse effects, therapeutic use)
• Isoindoles
• Male
• Middle Aged
• Receptor, Serotonin, 5-HT1A (drug effects)
• Schizophrenic Psychology
• Thiazoles (adverse effects, therapeutic use)
• Treatment Outcome